PharmaEssentia Corporation PharmaEssentia Corporation

PharmaEssentia Corporation

6446

Κατάταξη σε μετοχές #1420
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Τιμή μετοχής
$37.84
Κεφαλαιοποίηση
$15.65B
Αλλαγή (1 ημέρα)
3.03%
Αλλαγή (1 έτος)
148.76%
Χώρα
TW
Εμπόριο PharmaEssentia Corporation (6446)

Κατηγορία

Healthcare
Δείκτης P/S για PharmaEssentia Corporation (6446)
Δείκτης P/S στις October 2026 TTM: 23.96
Σύμφωνα με τις τελευταίες οικονομικές αναφορές και την τιμή μετοχής της PharmaEssentia Corporation, ο τρέχων δείκτης P/S (TTM) είναι 23.96. Στο τέλος του 2023, ο δείκτης ήταν 22.06.
Ιστορικό P/S για την PharmaEssentia Corporation από 2010 έως 2026
Δείκτης P/S στο τέλος κάθε έτους
Έτος P/S Ratio Αλλαγή
2026 (TTM) 23.96 16.52%
2024 20.56 -6.80%
2023 22.06 -53.07%
2022 47.01 -58.98%
2021 114.59 181.19%
2020 40.75 -46.81%
2019 76.61 -94.54%
2018 1.40K -81.75%
2017 7.68K 27.57%
2016 6.02K 95.48%
2015 3.08K 61.64%
2014 1.91K 276.50%
2013 506.34 -45.75%
2012 933.30 -41.98%
2011 1.61K 237.00%
2010 477.29 0.00%
Δείκτης P/S για παρόμοιες εταιρείες ή ανταγωνιστές